Dexcom's market growth accelerates with clinical wins and new paediatric approval amid intensifying competition

Dexcom’s latest quarter highlights a 13% revenue rise driven by clinical advances and FDA clearance for paediatric use, as the company aims to outpace rivals in a crowded CGM market, despite operational challenges.

Dexcom’s latest quarter gave investors several reasons to stay optimistic, even as the continuous glucose monitoring market becomes more crowded. The company said revenue rose 13% year on year to $1.3bn, helped by stronger demand and a clinical read-out that points to a much larger audience for its technology than the one it has traditionally served.

The most striking development was the CONNECT trial, which suggested Dexcom’s G7 can materially improve glucose control in people with type 2 diabetes who do not use insulin. According to the company’s figures, the study enrolled 265 patients and found average A1C fell by 1.6% after 26 weeks, with larger gains among those starting from higher levels. That matters because this group has often relied on finger-prick testing and sporadic lab work, leaving a sizeable commercial opportunity if insurers and doctors are persuaded by the evidence.

Dexcom also broadened its consumer strategy with FDA clearance for Stelo in children, making it the first over-the-counter CGM authorised for paediatric prediabetes and diabetes use. The company paired that approval with a redesigned app aimed at making the product easier to use for families paying out of pocket. In a market where convenience and engagement can determine whether a device is adopted or abandoned, the software experience may be nearly as important as the sensor itself.

Financially, the quarter showed far more than top-line growth. Dexcom reported GAAP operating income of $318.3m, equal to 24.3% of revenue, while non-GAAP operating income reached $328.3m, or 25.1%. Non-GAAP gross margin improved to 64.1% from 60.1% a year earlier, and the company ended the period with $1.95bn in cash, cash equivalents and marketable securities. Dexcom also lifted its full-year revenue and margin outlook, a sign that management believes the recent progress is not a one-off.

Analysts largely welcomed the numbers. William Blair maintained a buy stance but warned that growth is increasingly dependent on newer patient segments, where clinical evidence and reimbursement can be less established and competition more intense. BTIG also reiterated a buy rating and raised its price target, arguing that CGM should become the dominant way to monitor glucose for many patients over time, supported by remote monitoring, better accuracy and a more consumer-friendly model.

That competitive pressure is real. Abbott remains the biggest rival in CGM, while Medtronic and Senseonics are pushing their own approaches, including Senseonics’ fully implantable vision and Abbott’s newer glucose-ketone technology in Europe. Dexcom has had operational and reputational setbacks this year too, including problems around stolen G7 sensor lots and customer complaints about sensor failures. The company’s challenge now is to convert clinical wins, broader access and improved margins into durable growth before rivals close the gap.